News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News AHA 2022 In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE Todd Neale November 05, 2022
News Conference News AHA 2020 No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk Michael O'Riordan November 19, 2020
News Conference News AHA 2019 Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR Todd Neale November 17, 2019
News Conference News AHA 2017 Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery Shelley Wood November 14, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2016 No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION Shelley Wood November 13, 2016
News Conference News AHA 2016 Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients Yael L. Maxwell November 13, 2016